多功能蛋白聚糖(VCAN)重組蛋白
Recombinant Versican (VCAN)
CSPG2; VS; ERVR; PG-M; WGN1; Chondroitin Sulfate Proteoglycan 2; Chondroitin sulfate proteoglycan core protein 2; Glial hyaluronate-binding; Large fibroblast proteoglycan
- 編號RPB817Hu01
- 物種Homo sapiens (Human,人) 相同的名稱,不同的物種。
- 來源原核表達(dá)
- 宿主E.coli
- 內(nèi)毒素水平<1.0EU/µg(LAL法測定)
- 亞細(xì)胞定位分泌, 細(xì)胞外基質(zhì)
- 預(yù)測分子量31.1kDa
- 實(shí)際分子量38kDa(差異分析請參閱說明書)
- 片段與標(biāo)簽Thr2958~Ser3209 with N-terminal His Tag
- 緩沖液成份PBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
- 性狀凍干粉
- 純度> 90%
- 等電點(diǎn)4.8
-
應(yīng)用
Positive Control; Immunogen; SDS-PAGE; WB.
如果需要有生物活性的蛋白,請參見活性蛋白。 - 下載 英文說明書 中文說明書
- 規(guī)格 10μg50μg 200μg 1mg 5mg
- 價格 ¥ 960 ¥ 2400 ¥ 4800 ¥ 14400 ¥ 36000
- 欲了解實(shí)際交易價格和更多情況,請與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
序列
用法
Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
儲存
避免反復(fù)凍融。2-8°C不超過一個月,-80°C不超過12個月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗(yàn)決定,具體方法如下:在37°C孵育48小時,沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi),在適當(dāng)?shù)臈l件下存儲,損失率低于5%。
增值服務(wù)
相關(guān)產(chǎn)品
編號 | 適用物種:Homo sapiens (Human,人) | 應(yīng)用(僅供研究使用,不用于臨床診斷!) |
RPB817Hu02 | 多功能蛋白聚糖(VCAN)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
RPB817Hu01 | 多功能蛋白聚糖(VCAN)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
PAB817Hu01 | 多功能蛋白聚糖(VCAN)多克隆抗體 | WB,IHC |
PAB817Hu02 | 多功能蛋白聚糖(VCAN)多克隆抗體 | WB; IHC; ICC; IP. |
MAB817Hu22 | 多功能蛋白聚糖(VCAN)單克隆抗體 | WB; IHC; ICC; IP. |
SEB817Hu | 多功能蛋白聚糖(VCAN)檢測試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
SCB817Hu | 多功能蛋白聚糖(VCAN)檢測試劑盒(化學(xué)發(fā)光免疫分析法) | Chemiluminescent immunoassay for Antigen Detection. |
LMB817Hu | 多功能蛋白聚糖(VCAN)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
雜志 | 參考文獻(xiàn) |
Plos one | Tumor-Produced Versican V1 Enhances hCAP18/LL-37 Expression in Macrophages through Activation of TLR2 and Vitamin D3 Signaling to Promote Ovarian Cancer Progression In Vitro [PubMed: PMC3570526] |
Clinica Chimica Acta | Versican and its associated molecules: Potential diagnostic markers for multiple myeloma [Pubmed:25623955] |
Journal of Cancer Research and Clinical Oncology | Clinical significance of circulatory microRNA-203 in serum as novel potential diagnostic marker for multiple myeloma [] |
RNA Biology | Targeting of stromal versican by miR-144/199 inhibits multiple myeloma by downregulating FAK/STAT3 signaling [Pubmed: 31532704] |
miR-124-3p and miR-181a-5p Mediate AT1-Receptor Autoantibody Induced Fetal Rat Cardiac Remodeling via Increased VCAN Expression [] |
留言咨詢